Role of Serum (B/A) Ratio Compared to (TSB) for Early Prediction of Bilirubin-induced Neurological Dysfunction (BIND).

Launched by ALAA ABOELHASSAN MOHAMED ABOELHASSAN · Sep 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a blood test called the serum bilirubin/albumin (B/A) ratio can predict the risk of brain problems caused by high bilirubin levels in newborns. Bilirubin is a substance that can build up in a baby’s blood, leading to a condition called hyperbilirubinemia, which sometimes requires treatment like light therapy or a blood exchange. The researchers want to see if measuring the B/A ratio is a better early indicator of potential neurological issues compared to the standard method of measuring total serum bilirubin (TSB).

To participate in this study, babies must be between 1 and 28 days old and have hyperbilirubinemia severe enough to need treatment based on guidelines from the American Academy of Pediatrics. The trial is open to both full-term and preterm babies of any gender. However, babies with certain conditions, such as those with liver issues, severe birth defects, or other serious health problems, will not be included. If your baby qualifies and you choose to participate, you will help researchers understand how to better predict and manage the risks associated with high bilirubin levels, ultimately improving care for newborns.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria:• Neonates with hyperbilirubinemia reached level of phototherapy or exchange transfusion according to the American Academy of Pediatrics guidelines \[14\].
• • Age: from 1 to 28 day.
• • Full term and preterm babies.
• • Both sexes.
• Exclusion Criteria:
• • Conjugated hyperbilirubinemia.
• • Perinatal asphyxia.
• • Patients with encephalopathy due to causes other than hyperbilirubinemia.
• • Severe birth defects or congenital anomalies.
• • Hemodynamic instability.
• • Septic patients.